

Michiel Adreanus van de Sande

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6777257/publications.pdf>

Version: 2024-02-01

152
papers

4,783
citations

101496

36
h-index

128225

60
g-index

160
all docs

160
docs citations

160
times ranked

3932
citing authors

#	ARTICLE	IF	CITATIONS
1	Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort?. <i>European Journal of Surgical Oncology</i> , 2022, 48, 500-507.	0.5	7
2	Intraosseous hibernoma of the appendicular skeleton. <i>Skeletal Radiology</i> , 2022, 51, 1325-1330.	1.2	3
3	Infantile fibrosarcoma with an EGFR kinase domain duplication: Underlining a close relationship with congenital mesoblastic nephroma and highlighting a similar morphological spectrum. <i>Annals of Diagnostic Pathology</i> , 2022, 57, 151885.	0.6	5
4	Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors. <i>JAMA Oncology</i> , 2022, 8, 345.	3.4	46
5	MRI radiomics-based machine learning classification of atypical cartilaginous tumour and grade II chondrosarcoma of long bones. <i>EBioMedicine</i> , 2022, 75, 103757.	2.7	37
6	Multimodality treatment of undifferentiated pleomorphic soft tissue sarcoma of the extremity (eUPS) in the elderly. <i>European Journal of Surgical Oncology</i> , 2022, 48, 985-993.	0.5	3
7	What Do We Know about Survival in Skeletally Premature Children Aged 0 to 10 Years with Ewing Sarcoma? A Multicenter 10-Year Follow-Up Study in 60 Patients. <i>Cancers</i> , 2022, 14, 1456.	1.7	6
8	Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American) Tj ETQq0 0.0 rrgBT /Overlock 10	0.8	1
9	The added value of chest imaging after neoadjuvant radiotherapy for soft tissue sarcoma of the extremities and trunk wall: A retrospective cohort study. <i>European Journal of Surgical Oncology</i> , 2022, , .	0.5	1
10	The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC. <i>European Journal of Cancer</i> , 2022, 165, 71-80.	1.3	8
11	Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 333-345.	1.5	7
12	Malignant Transformation of Giant Cell Tumor of Bone and the Association with Denosumab Treatment: A Radiology and Pathology Perspective. <i>Sarcoma</i> , 2022, 2022, 1-12.	0.7	2
13	Surgical management of 144 diffuse-type TGCT patients in a single institution: A 20-year cohort study. <i>Journal of Surgical Oncology</i> , 2022, 126, 1087-1095.	0.8	9
14	MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS11590-TPS11590.	0.8	3
15	Surgical challenges, novel techniques, and systemic treatment of giant cell tumour of bone of the distal radius. <i>Bone & Joint Open</i> , 2022, 3, 515-528.	1.1	3
16	Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 480-492.	1.0	8
17	Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. <i>Oncologist</i> , 2021, 26, e863-e873.	1.9	28
18	Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. <i>Cancer</i> , 2021, 127, 884-893.	2.0	29

#	ARTICLE	IF	CITATIONS
19	Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center. <i>Cancers</i> , 2021, 13, 486.	1.7	12
20	The age-related impact of surviving sarcoma on health-related quality of life: data from the SURVSARC study. <i>ESMO Open</i> , 2021, 6, 100047.	2.0	12
21	Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review. <i>Cancers</i> , 2021, 13, 557.	1.7	10
22	The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 191.	1.2	25
23	Personalising sarcoma care using quantitative multimodality imaging for response assessment. <i>Clinical Radiology</i> , 2021, 76, 313.e1-313.e13.	0.5	7
24	Treatment Strategies for Metastatic Soft Tissue Sarcomas. <i>Cancers</i> , 2021, 13, 1722.	1.7	5
25	Management of tenosynovial giant cell tumour of the foot and ankle. <i>Bone and Joint Journal</i> , 2021, 103-B, 788-794.	1.9	10
26	Management of Soft Tissue Sarcomas in Extremities: Variation in Treatment Recommendations and Surveillance According to Specialty and Continent. <i>Annals of Surgical Oncology</i> , 2021, 28, 7923-7936.	0.7	12
27	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2021, 92, 493-499.	1.2	13
28	Health-related quality of life after isolated limb perfusion compared to extended resection, or amputation for locally advanced extremity sarcoma: Is a limb salvage strategy worth the effort?. <i>Journal of Clinical Oncology</i> , 2021, 39, e23539-e23539.	0.8	0
29	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021, 6, 100170.	2.0	65
30	Regression of fibrous dysplasia in response to denosumab therapy: A report of two cases. <i>Bone Reports</i> , 2021, 14, 101058.	0.2	9
31	Soft tissue and visceral sarcomas: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upâ††. <i>Annals of Oncology</i> , 2021, 32, 1348-1365.	0.6	381
32	Comparison of the 7th and 8th version of the AJCC classification system for soft tissue sarcomas of extremities and trunk in patients with localised, intermediate or high-grade disease treated at European tertiary sarcoma centres. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2182-2188.	0.5	4
33	Biology and technology in the surgical treatment of malignant bone tumours in children and adolescents, with a special note on the very young. <i>Journal of Children's Orthopaedics</i> , 2021, 15, 322-330.	0.4	3
34	Exposureâ€“response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1422-1432.	1.3	7
35	Bone sarcomas: ESMOâ€“EURACANâ€“GENTURISâ€“ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 1520-1536.	0.6	150
36	Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review. <i>Biomedicines</i> , 2021, 9, 1388.	1.4	14

#	ARTICLE	IF	CITATIONS
37	The Influence of Personalised Sarcoma Care (PERSARC) Prediction Modelling on Clinical Decision Making in a Multidisciplinary Setting. <i>Sarcoma</i> , 2021, 2021, 1-6.	0.7	4
38	The Association of Metastasis Pattern and Management of Metastatic Disease with Oncological Outcomes in Patients with Malignant Peripheral Nerve Sheath Tumors: A Multicenter Cohort Study. <i>Cancers</i> , 2021, 13, 5115.	1.7	5
39	External validation and adaptation of a dynamic prediction model for patients with high-grade extremity soft tissue sarcoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 1050-1056.	0.8	16
40	Prognostic Value of Quantitative [18F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma. <i>Diagnostics</i> , 2021, 11, 2271.	1.3	3
41	Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28138.	0.8	20
42	A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. <i>European Journal of Cancer</i> , 2020, 124, 77-87.	1.3	54
43	Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma. <i>Oncologist</i> , 2020, 25, e716-e721.	1.9	8
44	Individualizing Follow-Up Strategies in High-Grade Soft Tissue Sarcoma with Flexible Parametric Competing Risk Regression Models. <i>Cancers</i> , 2020, 12, 47.	1.7	12
45	Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 1703-1713.	1.4	12
46	Patient and diagnostic intervals of survivors of sarcoma: Results from the SURVSARC study. <i>Cancer</i> , 2020, 126, 5283-5292.	2.0	19
47	Seeking international consensus on approaches to primary tumour treatment in Ewing sarcoma. <i>Clinical Sarcoma Research</i> , 2020, 10, 21.	2.3	14
48	Development and external validation of nomograms to predict sarcoma-specific death and disease progression after surgical resection of localized high-grade conventional primary central chondrosarcoma and dedifferentiated chondrosarcoma. <i>Bone and Joint Journal</i> , 2020, 102-B, 1752-1759.	1.9	8
49	Age-related differences of oncological outcomes in primary extremity soft tissue sarcoma: a multistate model including 6260 patients. <i>European Journal of Cancer</i> , 2020, 141, 128-136.	1.3	13
50	Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease. <i>Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews</i> , 2020, 4, e20.00028.	0.4	21
51	Time Trends and Prognostic Factors for Overall Survival in Myxoid Liposarcomas: A Population-Based Study. <i>Sarcoma</i> , 2020, 2020, 1-8.	0.7	10
52	Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor. <i>Future Oncology</i> , 2020, 16, 2345-2356.	1.1	22
53	The Perceived Impact of Length of the Diagnostic Pathway Is Associated with Health-Related Quality of Life of Sarcoma Survivors: Results from the Dutch Nationwide SURVSARC Study. <i>Cancers</i> , 2020, 12, 2088.	1.7	7
54	Clinical Outcome of Surgically Treated Leiomyosarcoma of the Extremities: A Retrospective Overview. <i>Anticancer Research</i> , 2020, 40, 5319-5325.	0.5	2

#	ARTICLE	IF	CITATIONS
55	The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT. <i>Surgical Oncology</i> , 2020, 35, 261-267.	0.8	11
56	Unraveling the Heterogeneity of Sarcoma Survivorsâ€™ Health-Related Quality of Life Regarding Primary Sarcoma Location: Results from the SURVSARC Study. <i>Cancers</i> , 2020, 12, 3083.	1.7	22
57	Current concepts in the treatment of giant cell tumour of bone. <i>Current Opinion in Oncology</i> , 2020, 32, 332-338.	1.1	21
58	Long-Term Clinical Outcomes of Intercalary Allograft Reconstruction for Lower-Extremity Bone Tumors. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 1042-1049.	1.4	28
59	Expandable distal femur megaprosthesis: A European Musculoskeletal Oncology Society study on 299 cases. <i>Journal of Surgical Oncology</i> , 2020, 122, 760-765.	0.8	17
60	Can we use MRI to detect clinically silent recurrent soft-tissue sarcoma?. <i>European Radiology</i> , 2020, 30, 4724-4733.	2.3	17
61	Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging. <i>Laboratory Investigation</i> , 2020, 100, 1252-1261.	1.7	20
62	Extrameningeal solitary fibrous tumorsâ€™ surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet. <i>Cancer</i> , 2020, 126, 3002-3012.	2.0	39
63	Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1729-1738.	3.1	23
64	Incidence, treatment and outcome of abdominal metastases in extremity soft tissue sarcoma: Results from a multi-centre study. <i>Journal of Surgical Oncology</i> , 2020, 121, 605-611.	0.8	7
65	Therapy-Related Imaging Findings in Patients with Sarcoma. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 676-691.	0.4	5
66	Patient and diagnostic intervals of sarcoma patients: Results from a survivorship study in the Netherlands.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23553-e23553.	0.8	0
67	Patient journey and quality of life (QOL) among diffuse-type TGCT in the U.S.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23565-e23565.	0.8	0
68	Surgery for metachronous metastasis of soft tissue sarcoma â€“ A magnitude of benefit analysis using propensity score methods. <i>European Journal of Surgical Oncology</i> , 2019, 45, 242-248.	0.5	15
69	Screening program for neonates at risk for developmental dysplasia of the hip: comparing first radiographic evaluation at five months with the standard twelve week ultrasound. A prospective cross-sectional cohort study. <i>International Orthopaedics</i> , 2019, 43, 1933-1938.	0.9	10
70	Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?. <i>Histopathology</i> , 2019, 74, 332-340.	1.6	28
71	Radiologic differentiation of enchondromas, atypical cartilaginous tumors, and high-grade chondrosarcomasâ€™ Improving tumor-specific treatment: A paradigm in transit?. <i>Cancer</i> , 2019, 125, 3288-3291.	2.0	23
72	Assessing quality of life and experiences of diagnostic trajectories of sarcoma patients: The QUEST study protocol. <i>Annals of Oncology</i> , 2019, 30, v709.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Prevalence and Clinical Features of Mazabraud Syndrome. <i>Journal of Bone and Joint Surgery - Series A</i> , 2019, 101, 160-168.	1.4	21
74	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet, The</i> , 2019, 394, 478-487.	6.3	273
75	Resuscitating extremities after soft tissue sarcoma resections: Are functional reconstructions an overlooked option in limb salvage? A systematic review. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1762-1769.	0.5	16
76	Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2019, 20, 877-886.	5.1	75
77	18F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma. <i>Skeletal Radiology</i> , 2019, 48, 1735-1746.	1.2	18
78	The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function. <i>Bone and Joint Journal</i> , 2019, 101-B, 272-280.	1.9	15
79	Bone sarcoma incidence in the Netherlands. <i>Cancer Epidemiology</i> , 2019, 60, 31-38.	0.8	18
80	Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. <i>EClinicalMedicine</i> , 2019, 17, 100215.	3.2	42
81	Multiflora and Gram-Negative Microorganisms Predominate in Infections Affecting Pelvic Endoprostheses Following Tumor Resection. <i>Journal of Bone and Joint Surgery - Series A</i> , 2019, 101, 797-803.	1.4	12
82	Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints. <i>Journal of Bone and Joint Surgery - Series A</i> , 2019, 101, 1309-1318.	1.4	30
83	Time dependent dynamics of wound complications after preoperative radiotherapy in Extremity Soft Tissue Sarcomas. <i>European Journal of Surgical Oncology</i> , 2019, 45, 684-690.	0.5	23
84	Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11042-11042.	0.8	4
85	Considering sarcoma staging systems and their implications to personalized care. <i>Chinese Clinical Oncology</i> , 2019, 8, S9-S9.	0.4	0
86	Conventional Primary Central Chondrosarcoma of the Pelvis. <i>Journal of Bone and Joint Surgery - Series A</i> , 2018, 100, 316-325.	1.4	72
87	Outcome of acute staphylococcal prosthetic joint infection treated with debridement, implant retention and antimicrobial treatment with short duration of rifampicin. <i>Journal of Infection</i> , 2018, 76, 498-500.	1.7	14
88	Successful disinfection of femoral head bone graft using high hydrostatic pressure. <i>Cell and Tissue Banking</i> , 2018, 19, 333-340.	0.5	4
89	Reliability of the classification of proximal femur fractures: Does clinical experience matter?. <i>Injury</i> , 2018, 49, 819-823.	0.7	32
90	Perioperative Management of Extremity Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 118-124.	0.8	33

#	ARTICLE	IF	CITATIONS
91	Trends in the surgical treatment of pathological fractures of the long bones. Bone and Joint Journal, 2018, 100-B, 1392-1398.	1.9	7
92	Dynamic prediction of overall survival for patients with high-grade extremity soft tissue sarcoma. Surgical Oncology, 2018, 27, 695-701.	0.8	33
93	Tenosynovial Giant Cell Tumors in Children: A Similar Entity Compared With Adults. Clinical Orthopaedics and Related Research, 2018, 476, 1803-1812.	0.7	10
94	What Factors Are Associated With Implant Breakage and Revision After Intramedullary Nailing for Femoral Metastases?. Clinical Orthopaedics and Related Research, 2018, 476, 1823-1833.	0.7	31
95	Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. Surgical Oncology, 2018, 27, 402-408.	0.8	116
96	Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study. Monthly Notices of the Royal Astronomical Society: Letters, 2018, 89, 570-574.	1.2	39
97	Individualized approach to the surgical management of fibrous dysplasia of the proximal femur. Orphanet Journal of Rare Diseases, 2018, 13, 72.	1.2	20
98	Severity classification of Tenosynovial Giant Cell Tumours on MR imaging. Surgical Oncology, 2018, 27, 544-550.	0.8	31
99	Radiation Therapy as Sole Management for Solitary Fibrous Tumors (SFT): A Retrospective Study From the Global SFT Initiative in Collaboration With the Sarcoma Patients EuroNet. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1226-1233.	0.4	39
100	First prospective observational study in diffuse-type tenosynovial giant cell tumors.. Journal of Clinical Oncology, 2018, 36, 11560-11560.	0.8	2
101	The Patient Perspective on the Impact of Tenosynovial Giant Cell Tumors on Daily Living: Crowdsourcing Study on Physical Function and Quality of Life. Interactive Journal of Medical Research, 2018, 7, e4.	0.6	28
102	What Are the Long-term Results of MUTARSÂ® Modular Endoprostheses for Reconstruction of Tumor Resection of the Distal Femur and Proximal Tibia?. Clinical Orthopaedics and Related Research, 2017, 475, 708-718.	0.7	86
103	What Is the Role of Allogeneic Cortical Strut Grafts in the Treatment of Fibrous Dysplasia of the Proximal Femur?. Clinical Orthopaedics and Related Research, 2017, 475, 786-795.	0.7	26
104	LUMiCÂ® Endoprosthetic Reconstruction After Periacetabular Tumor Resection: Short-term Results. Clinical Orthopaedics and Related Research, 2017, 475, 686-695.	0.7	87
105	Individualised risk assessment for local recurrence and distant metastases in a retrospective transatlantic cohort of 687 patients with high-grade soft tissue sarcomas of the extremities: a multistate model. BMJ Open, 2017, 7, e012930.	0.8	39
106	Is there still a role for osteoarticular allograft reconstruction in musculoskeletal tumour surgery?. Bone and Joint Journal, 2017, 99-B, 522-530.	1.9	62
107	Long-term impairment attributable to congenital cytomegalovirus infection: a retrospective cohort study. Developmental Medicine and Child Neurology, 2017, 59, 1261-1268.	1.1	55
108	Higher incidence rates than previously known in tenosynovial giant cell tumors. Monthly Notices of the Royal Astronomical Society: Letters, 2017, 88, 688-694.	1.2	87

#	ARTICLE	IF	CITATIONS
109	A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: Personalised sarcoma care (PERSARC). <i>European Journal of Cancer</i> , 2017, 83, 313-323.	1.3	63
110	Determinants of impaired quality of life in patients with fibrous dysplasia. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 80.	1.2	24
111	Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 264-276.	3.1	70
112	Cross-Cultural Adaptation, Translation, and Validation of the Toronto Extremity Salvage Score for Extremity Bone and Soft Tissue Tumor Patients in Netherlands. <i>Sarcoma</i> , 2017, 2017, 1-6.	0.7	11
113	Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases. <i>Case Reports in Orthopedics</i> , 2017, 2017, 1-6.	0.1	10
114	Treatment of Prosthetic Joint Infection: Debridement, Antibiotics and Implant Retention With Short Duration of Rifampicin. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
115	Treatment of pathological fractures of the long bones. <i>EFORT Open Reviews</i> , 2016, 1, 136-145.	1.8	76
116	Pigmented villonodular synovitis: a crowdsourcing study of two hundred and seventy two patients. <i>International Orthopaedics</i> , 2016, 40, 2459-2468.	0.9	28
117	Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma. <i>Endocrine</i> , 2016, 54, 642-647.	1.1	8
118	Prophylactic antibiotic regimens in tumour surgery (PARITY). <i>Bone and Joint Research</i> , 2015, 4, 154-162.	1.3	23
119	Translation and adaptation of the Pediatric Outcome Data Collecting Instrument (PODCI) into the Dutch language and preliminary validation in children with Neonatal Brachial Plexus Palsy. <i>Journal of Pediatric Rehabilitation Medicine</i> , 2015, 8, 219-226.	0.3	10
120	Fusion events lead to truncation of <i>FOS</i> in epithelioid hemangioma of bone. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 565-574.	1.5	69
121	High-grade soft tissue sarcomas of the extremities: surgical margins influence only local recurrence not overall survival. <i>International Orthopaedics</i> , 2015, 39, 935-941.	0.9	31
122	Ext1 heterozygosity causes a modest effect on postprandial lipid clearance in humans. <i>Journal of Lipid Research</i> , 2015, 56, 665-673.	2.0	22
123	Neoadjuvant denosumab for extensive giant cell tumor in os ischium – a case report. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2015, 86, 393-395.	1.2	14
124	Use of the Composite Pedicled Pectoralis Minor Flap after Resection of Soft Tissue Sarcoma in Reconstruction of the Glenohumeral Joint. <i>Case Reports in Orthopedics</i> , 2014, 2014, 1-5.	0.1	2
125	The Clinical Approach Toward Giant Cell Tumor of Bone. <i>Oncologist</i> , 2014, 19, 550-561.	1.9	199
126	Can Orthopedic Oncologists Predict Functional Outcome in Patients with Sarcoma after Limb Salvage Surgery in the Lower Limb? A Nationwide Study. <i>Sarcoma</i> , 2014, 2014, 1-11.	0.7	10

#	ARTICLE	IF	CITATIONS
127	Intercalary Allograft Reconstructions Following Resection of Primary Bone Tumors. Journal of Bone and Joint Surgery - Series A, 2014, 96, e26.	1.4	117
128	Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer, 2014, 120, 3159-3164.	2.0	83
129	Loss of Function in Heparan Sulfate Elongation Genes EXT1 and EXT 2 Results in Improved Nitric Oxide Bioavailability and Endothelial Function. Journal of the American Heart Association, 2014, 3, e001274.	1.6	20
130	In Reply. Oncologist, 2014, 19, 1208-1208.	1.9	0
131	Interobserver Variability in the Treatment of Little Finger Metacarpal Neck Fractures. Journal of Hand Surgery, 2014, 39, 1722-1727.	0.7	21
132	Liquid Nitrogen or Phenolization for Giant Cell Tumor of Bone?. Journal of Bone and Joint Surgery - Series A, 2014, 96, e35.	1.4	48
133	Giant cell tumors of the sacrum—a nationwide study on midterm results in 26 patients after intralesional excision. European Spine Journal, 2014, 23, 1949-1962.	1.0	22
134	Carriers of Loss-of-Function Mutations in EXT Display Impaired Pancreatic Beta-Cell Reserve Due to Smaller Pancreas Volume. PLoS ONE, 2014, 9, e115662.	1.1	12
135	A multidisciplinary approach to giant cell tumors of tendon sheath and synovium—A critical appraisal of literature and treatment proposal. Journal of Surgical Oncology, 2013, 107, 433-445.	0.8	60
136	Surgical Technique: Tibia Cortical Strut Autograft Interposition Arthrodesis After Distal Radius Resection. Clinical Orthopaedics and Related Research, 2013, 471, 803-813.	0.7	16
137	Giant Cell Tumor With Pathologic Fracture: Should We Curette or Resect?. Clinical Orthopaedics and Related Research, 2013, 471, 820-829.	0.7	76
138	Mid-Term Outcome After Curettage with Polymethylmethacrylate for Giant Cell Tumor Around the Knee: Higher Risk of Radiographic Osteoarthritis?. Journal of Bone and Joint Surgery - Series A, 2013, 95, e159.	1.4	45
139	The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis). Journal of Bone and Joint Surgery: British Volume, 2012, 94-B, 882-888.	3.4	69
140	Successful Pavlik treatment in late-diagnosed developmental dysplasia of the hip. International Orthopaedics, 2012, 36, 1661-1668.	0.9	19
141	Proximal humerus reconstruction after tumour resection: biological versus endoprosthetic reconstruction. International Orthopaedics, 2011, 35, 1375-1380.	0.9	94
142	Range of motion implications of proximal humerus fractures: a case study. European Orthopaedics and Traumatology, 2011, 2, 153-156.	0.1	6
143	Cartilage “Forming Bone Tumours. , 2011, , 23-44.		0
144	Teres major muscle activation relates to clinical outcome in tendon transfer surgery. Clinical Biomechanics, 2010, 25, 187-193.	0.5	38

#	ARTICLE	IF	CITATIONS
145	Clinical implications of rotator cuff degeneration in the rheumatic shoulder. <i>Arthritis and Rheumatism</i> , 2008, 59, 317-324.	6.7	24
146	Comparison between tripod and skin-fixed recording of scapular motion. <i>Journal of Biomechanics</i> , 2007, 40, 941-946.	0.9	113
147	Pathological Teres Major activation in patients with massive rotator cuff tears alters with pain relief and/or salvage surgery transfer. <i>Clinical Biomechanics</i> , 2006, 21, S27-S32.	0.5	30
148	Pathological muscle activation patterns in patients with massive rotator cuff tears, with and without subacromial anaesthetics. <i>Manual Therapy</i> , 2006, 11, 231-237.	1.6	77
149	Indications, complications, and results of shoulder arthroplasty. <i>Scandinavian Journal of Rheumatology</i> , 2006, 35, 426-434.	0.6	72
150	Quantitative Assessment of Fatty Degeneration in Rotator Cuff Muscles Determined With Computed Tomography. <i>Investigative Radiology</i> , 2005, 40, 313-319.	3.5	47
151	Modular total shoulder system with short stem. A prospective clinical and radiological analysis. <i>International Orthopaedics</i> , 2004, 28, 115-118.	0.9	14
152	Outcome of Surgical Treatment for Patients with Diffuse-Type Tenosynovial Giant Cell Tumours. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4